ArticleAsian Pacific journal of cancer prevention : APJCP2025
The Predictive Significance of Galectin 3 Expression in Patients with Unresectable Non-Small Cell Lung Cancer without EGFR or ALK Mutations Treated Platinum-Based Doublet Chemotherapy.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of our study is to evaluate the predictive value of cytoplasmic Galectin-3 (Gal-3) expression in tumor cells (TCs) as well as in tumor-infiltrating immune cells (TIICs), including tumor-associated macrophages (TAM), tumor-associated neutrophils (TAN), and tumor-associated lymphocytes (TAL), in Moroccan patients with unresectable non-small cell lung cancer (NSCLC).
methodsThis is a prospective study conducted between 2019 and 2023 on 56 Moroccan patients diagnosed with unresectable NSCLC. These patients were treated with platinum-based doublet chemotherapy and followed at the Mohammed VI Center for Cancer Treatment at CHU Ibn Rochd in Casablanca. Immunohistochemistry (IHC) was used to assess Gal-3 (clone 9C4) expression in TCs and TIICs (TAM, TAN, and TAL). The characteristics of the patients were obtained from the patients' medical records. Statistical analysis, including Kaplan-Meier survival analysis and Cox regression, was performed using SPSS v.21.
resultsSurvival analysis across different subgroups revealed that only patients with high Gal-3 expression in TCs, along with positive expression in TIICs or TAL, exhibited significantly improved overall survival (OS = 16.81 months, p = 0.007; OS = 15.95 months, p = 0.034) compared to other subgroups. Additionally, multivariate analysis showed that poor performance status (PS 1-2) and the presence of bone metastases were significantly associated with decreased progression-free survival (PFS) (p = 0.015 and p = 0.029, respectively). The histological type (squamous cell carcinoma) was significantly correlated with OS (p = 0.000).
conclusionThe concomitant expression of Gal-3 in TCs (high expression), TIICs, and TAL may serve as a predictive biomarker for chemotherapy response in patients with unresectable NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.